A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study

2012104 citationsJournal Articlehybrid Open Access

Authors

Yousuke Nakai · The University of Tokyo

Hiroyuki Isayama · The University of Tokyo

Takashi Sasaki · The University of Tokyo

Naoki Sasahira · The University of Tokyo

Takuya Tsujino · The University of Tokyo

Nobuo Toda · Mitsui Memorial Hospital

Hirofumi Kogure ·

Abstract

Gemcitabine and S-1 combination therapy demonstrated longer PFS in advanced pancreatic cancer. Improved OS duration of 4.7 months was found for gemcitabine and S-1 combination therapy, though this was not statistically significant.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Cholangiocarcinoma and Gallbladder Cancer Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 106, Issue 12, pp. 1934-1939

DOI: 10.1038/bjc.2012.183

Field-Weighted Citation Impact: 6.19